Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Enhertu trastuzumab deruxtecan Metastatic HER2 positive breast cancer Reimburse with clinical criteria and/or conditions Complete
Enhertu trastuzumab deruxtecan Metastatic HER2-positive breast cancer Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Enhertu trastuzumab deruxtecan Gastric or gastroesophageal junction (GEJ) adenocarcinoma Active
Enhertu trastuzumab deruxtecan unresectable or metastatic HER2-low breast cancer Reimburse with clinical criteria and/or conditions Complete
Enspryng satralizumab Neuromyelitis optica spectrum disorder Reimburse with clinical criteria and/or conditions Complete
Entresto sacubitril/valsartan Heart failure, NYHA Class II or III Reimburse with clinical criteria and/or conditions Complete
Entresto Sacubitril/valsartan Heart failure, NYHA class II or III List with clinical criteria and/or conditions Complete
Entuzity KwikPen human insulin Diabetes mellitus Reimburse with clinical criteria and/or conditions Complete
Entyvio vedolizumab Crohn’s disease Reimburse with clinical criteria and/or conditions Complete
Entyvio Vedolizumab Ulcerative colitis List with clinical criteria and/or conditions Complete
Entyvio Vedolizumab Crohn's disease Reimburse with clinical criteria and/or conditions Complete
Entyvio vedolizumab Ulcerative Colitis Reimburse with clinical criteria and/or conditions Complete
Epclusa sofosbuvir / velpatasvir Hepatitis C, chronic Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Epclusa Sofosbuvir/ velpatasvir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete
Epidiolex cannabidiol Lennox-Gastaut Syndrome (LGS) Reimburse with clinical criteria and/or conditions Complete
Epidiolex cannabidiol Dravet Syndrome (DS) Reimburse with clinical criteria and/or conditions Complete
Epidiolex cannabidiol Seizures associated with Tuberous Sclerosis Complex (TSC) Reimburse with clinical criteria and/or conditions Complete
Epkinly epcoritamab Relapsed or refractory diffuse large B-cell lymphoma Time-limited reimbursement recommendation Complete
Erbitux Cetuximab Cancelled
Erbitux Cetuximab Metastatic Colorectal Cancer Do not reimburse Complete
Erelzi Etanercept Rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete
Erivedge Vismodegib Basal Cell Carcinoma Reimburse with clinical criteria and/or conditions Complete
Erleada Apalutamide non-metastatic castrate resistant prostate cancer (nm-CRPC) Reimburse with clinical criteria and/or conditions Complete
Erleada Apalutamide metastatic castration-sensitive prostate cancer (mCSPC) Reimburse with clinical criteria and/or conditions Complete
Esbriet Pirfenidone Idiopathic pulmonary fibrosis Do not list Complete